In This Article:
Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating. Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early proof-of-concept data for this asset could lead to substantial upside, the analyst tells investors in a research note. The firm also believes significant value can be unlocked for ATI-045 in asthma and other large respiratory indications after upcoming China Phase 2 data.
Light Up your Portfolio with Spark:
-
Easily identify stocks' risks and opportunities.
-
Discover stocks' market position with detailed competitor analyses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACRS:
Questions or Comments about the article? Write to editor@tipranks.com